Brigham Buhler: They're monetizing your chronic disease

"Everyone can agree that if we could prevent cancer, why would we want to focus on treatments for cancer, right? If we can prevent diabetes, we don't have to write drugs to treat diabetes. These things are possible, but it requires getting proactive and predictive, and the system's not built to do that.

On average, a patient gets six minutes with a provider in this country. That's for that doctor to be able to troubleshoot family history go over all the elements that are bothering you, all the prescription medications you're on, which now the average American's on four or more prescription drugs.

It's virtually impossible to be able to cover that much ground in six minutes. I mean, it is impossible. Then if you look and you look through the layers of this, um, you would say, well, if you're an insurance company, isn't there value in preventing chronic diseases? Don't these, don't these cost us more money?

And the answer is yes. If a patient transitions from being pre-diabetic to diabetic, there is a six-fold increase in the cost of care for the rest of that patient's life. But when I tell you they're monetizing your chronic disease, I can walk you through how. So there's so many players in this and so often we're focused on the pharmaceutical companies and they're bad guys.

They are bad guys and and that's that's abundantly clear but separate from the big pharmaceutical Conglomerates are the big insurance conglomerates and they're just as sinister the big insurance companies are literally making rebates or kickbacks on every prescription drug you or your loved ones take."